Hennion & Walsh Asset Management, Inc. Theravance Biopharma, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$7.42 - $11.05 $464,091 - $691,133	-62,546 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$6.77 - $14.41 $18,279 - $38,907	-2,700 Reduced 4.14%	62,546 $463,000
Q2 2021 Aug 13, 2021	SELL	$14.52 - $22.46 $541,625 - $837,802	-37,302 Reduced 36.38%	65,246 $947,000
Q1 2021 May 17, 2021	BUY	$16.57 - $21.08 $1.7 Million - $2.16 Million	102,548 New	102,548 $2.09 Million

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.